Table 1.
Frequency of comorbidities in total atrial fibrillation patient population and among those treated with warfarin
| 60–69 years | 70–79 years | 80+ years (reference group) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group | All patients n (%) | Patients n (%) | Patients treated with warfarin n (%) | χ2 Value* | p Value* | Patients n (%) | Patients treated with warfarin n (%) | χ2 Value† | p Value† | Patients n (%) | Patients treated with warfarin n (%) |
| Number of patients | 81 381 | 17 054 | 9648 (57) | 2883 | <0.0001 | 30 350 | 16 641 (55) | 3453 | <0.0001 | 33 977 | 10 830 (32) |
| Women | 42 318 (52) | 6300 (37) | 3268 (52) | 1094 | <0.0001 | 14 315 (47) | 7433 (52) | 1849 | <0.0001 | 21 300 (63) | 6246 (29) |
| Men | 39 063 (48) | 10 754 (63) | 6380 (59) | 1254 | <0.0001 | 16 035 (53) | 9208 (57) | 1283 | <0.0001 | 12 677 (37) | 4584 (36) |
| BMI, mean (SD) | 27.1 (5.2) | 29.0 (5.9) | 29.5 (6.1) | 27.6 (5.2) | 28.0 (5.2) | 25.8 (4.7) | 26.5 (4.6) | ||||
| % with non-missing BMI | 85 | 87 | 74 | 87 | 74 | 82 | |||||
| Hypertension (diagnosed) | 44 841 (55) | 8362 (49) | 4951 (59) | 1461 | <0.0001 | 17 328 (57) | 9692 (56) | 1694 | <0.0001 | 19 151 (56) | 6603 (34) |
| Diabetes | 10 022 (12) | 2233 (13) | 1333 (60) | 377 | <0.0001 | 4291 (14) | 2358 (55) | 355 | <0.0001 | 3498 (10) | 1175 (34) |
| LVEF <40% | 2719 (3) | 723 (4) | 529 (73) | 109 | <0.0001 | 1165 (4) | 797 (68) | 92 | <0.0001 | 831 (2) | 391 (47) |
| Coronary heart disease | 19 860 (2) | 3531 (2) | 2088 (59) | 588 | <0.0001 | 8052 (27) | 4592 (57) | 794 | <0.0001 | 8277 (24) | 2901 (35) |
| Congestive heart failure | 21 075 (26) | 3094 (18) | 2152 (70) | 1277 | <0.0001 | 7401 (24) | 4490 (61) | 1296 | <0.0001 | 10 580 (31) | 3549 (34) |
| Stroke | 8142 (10) | 1264 (7) | 807 (64) | 369 | <0.0001 | 3084 (10) | 1760 (57) | 394 | <0.0001 | 3794 (11) | 1259 (33) |
| Stroke/TIA | 10 763 (13) | 1567 (9) | 1029 (66) | 496 | <0.0001 | 3928 (13) | 2299 (59) | 543 | <0.0001 | 5268 (16) | 1797 (34) |
| Alzheimer's/dementia | 5382 (7) | 187 (1) | 95 (51) | 121 | <0.0001 | 1519 (5) | 617 (41) | 294 | <0.0001 | 3676 (11) | 664 (18) |
| Thromboembolism‡ | 4619 (6) | 803 (5) | 554 (69) | 132 | <0.0001 | 1729 (6) | 1109 (64) | 137 | <0.0001 | 2087 (6) | 943 (45) |
| Vascular disease‡ | 12 389 (15) | 2 225 (13) | 1353 (61) | 418 | <0.0001 | 4997 (16) | 2847 (57) | 487 | <0.0001 | 5167 (15) | 1816 (35) |
| CHADS2 score | |||||||||||
| 0 | 10 241 (13) | 6243 (37) | 3072 (49) | – | – | 3998 (13) | 2038 (51) | – | – | 0 (0) | 0 (0) |
| 1 | 24 859 (31) | 6701 (39) | 3925 (59) | 1514 | <0.0001 | 9865 (33) | 5297 (54) | 1310 | <0.0001 | 8293 (24) | 2249 (27) |
| 2+ | 46 281 (57) | 4110 (24) | 2651 (65) | 1458 | <0.0001 | 16 487 (56) | 9306 (56) | 2181 | <0.0001 | 25 684 (76) | 8581 (33) |
| CHA2DS2 -VASc score | |||||||||||
| 0 | 1620 (2) | 1620 (9) | 798 (49) | – | – | 0 (0) | 0 (0) | – | – | 0 (0) | 0 (0) |
| 1 | 6276 (8) | 4348 (25) | 2292 (53) | – | – | 1928 (6) | 1028 (53) | – | – | 0 (0) | 0 (0) |
| 2+ | 73 485 (90) | 11 086 (65) | 6 558 (59) | 2625 | <0.0001 | 28 422 (94) | 15 613 (55) | 3370 | <0.0001 | 33 977 (100) | 10 830 (32) |
| HAS-BLED | |||||||||||
| 0–1 | 31 522 (39) | 10 337 (61) | 5805 (56) | 1169 | <0.0001 | 10 445 (34) | 5857 (56) | 1167 | <0.0001 | 10 740 (32) | 3518 (33) |
| 2+ | 49 859 (61) | 6717 (39) | 3843 (57) | 1478 | <0.0001 | 19 905 (66) | 10 784 (54) | 2271 | <0.0001 | 23 237 (68) | 7312 (31) |
*χ2 tests comparing the proportion of patients treated with warfarin in the 60–69 years age group compared with the 80+ years age group.
†χ2 tests comparing the proportion of patients treated with warfarin in the 70–79 years age group compared with the 80+ years age group.
‡Diagnostic codes used to define are shown in appendix S1.
BMI, body mass index; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack.